Low severity of GVHD, substantial graft vs tumor (GVT) and slow development of protective immunity are welldocumented features of cord blood transplants (CBT). We have evaluated the immune reconstitution of adult recipients of single-unit CBT supported by the coinfusion of third party donor (TPD) mobilized hematopoietic stem cells (MHSC), a procedure-'dual CB/TPD-MHSC transplant'-that results in early recovery of circulating granulocytes, high rates of CB engraftment and full chimerism. Cumulative recovery of natural killer and B cells at or above the median values of normal controls were 1.0 and 0.76 by the sixth and ninth months. Recovery of T cells was much slower, naive cells lagging behind those of memory and effector (committed) immunophenotypes. Serial analyses of signal joint TCR excision circles showed a general pattern of very low levels by the third month after CBT, followed by recovery to levels persistently similar or higher than those observed before transplantation and in normal controls. Our results are consistent with the clinical observations of substantial GVT effect together with low incidence of serious GVHD and slow development of protective immunity and suggest that thymic function contributes substantially to the recovery of T-cell populations in adults receiving dual CB/TPD-MHSC transplants.
Introduction
Low incidence and severity of GVHD, substantial antitumor immunotherapeutic effect (GVT) and slow development of protective immunity are well documented features of cord blood transplants (CBT). The pathophysiology of this pattern of immunologically based manifestations is not well understood.
We developed a strategy of single unit CBT supported by the coinfusion of a relatively low number of T-cell-depleted mobilized hematopoietic stem cells (MHSC) from a third party donor (TPD) after myeloablative conditioning or reduced extra hematological toxicity (dual CB/TPD-MHSC). This strategy results in early recovery of circulating granulocytes and high rates of cord blood (CB) engraftment and full chimerism, making CBT with single units of relatively low cell content feasible in adults. 1, 2 In patients thus treated because of high-risk hematologic neoplasms, the main causes of morbidity and mortality are postengraftment opportunistic infections. Here we report data on the immune reconstitution of 30 adult recipients of dual CB/TPD-MHSC.
Design and methods

Design
Observational clinical study.
Regulatory requirements
The clinical protocol, including laboratory studies for evaluation of immune reconstitution, was approved by the Institutional Research and Ethics Committee for treatment of adult patients with high-risk hematological conditions. Written informed consent in accordance with the Helsinki Declaration (Ethical Principles for Medical Research Involving Human Subjects, 1964 and subsequent versions) was obtained from all patients or their legal representatives.
Patient eligibility, HLA typing and procurement of transplantation products All these were as previously described. [1] [2] [3] In brief, patients were eligible for enrollment if older than 15 years and diagnosed with a high relapse-risk hematologic neoplasm, including CML beyond the initial chronic phase; acute leukemia beyond first remission, with high-risk cytogenetics or poor response to induction chemotherapy; severe myelodysplasia; and high-grade lymphomas with poor response to chemotherapy. Patients included in this study are a subset of those included in a previous study focused on myeloid reconstitution:
2 the 30 patients who were transplanted between July 2004 and December 2007. The CB units were provided by different CB banks in the international network.
Preparative regimen and GVHD prophylaxis As previously described, 1, 2 for most patients the preparative regimen consisted of fractionated TBI to a total dose of 10 Gy in five fractions in 3 days (À8 to À6) with lungs shielded at 8 Gy, i.v. fludarabine (FDB), total dose of 120 mg/m 2 (30 mg/m 2 /day, days -5 to À2), i.v. CY, 120 mg/kg total dose (60 mg/kg/day over 1 h, days À3 and À2) and i.v. rabbit antithymocyte globulin (ATG; Timoglobulina, Genzyme, Marcy L'Etoile, France) 2 mg/kg days À2 and À1. Until 2006, BU, given orally 4 mg/kg/day on days À5 and À4, substituted for TBI when this was contraindicated. After 2006, i.v. Busilvex (Pierre-Fabre, Boulogne, France) was given instead (daily two 3.2 mg/kg doses) and one patient had this replaced by i.v. Ara-C (2 g/m 2 /day Â 5 days). The BUcontaining regimen was given to nine patients with myeloproliferative disease. Twenty patients with lymphoproliferative disease received the TBI-based preparative regimen and one received AraC þ CY þ FDB þ ATG because of previous craniospinal irradiation.
CsA was begun i.v. on day -5 at a dose of 3 mg/kg daily, adjusted to a serum level of 180-250 ng/ml, changed to the oral route as soon as tolerance allowed. It was continued until full CB engraftment was achieved, at which point tapering was immediately initiated if there were no signs of GVHD. Methylprednisolone was given i.v. at a dose of 1 mg/kg from day -1 to days þ 10 to þ 14 and was rapidly tapered thereafter unless there was clinical indication for its maintenance. G-CSF was initiated on day þ 1 at a dose of 30 MU daily and continued until a sustained ANC higher than 1 Â 10 9 /l was reached. The dose was then adjusted as required to maintain the ANC above this level.
Nursing, infection prophylaxis and protocols for transfusion support and infection treatments were as previously described.
1,2 Corticosteroid-based treatment (methylprednisolone 1-2 mg/kg/day) was given when grade II or higher acute GVHD (a-GVHD) developed.
Definitions and assessments of hematopoietic recovery, chimerism and transplant-related events All these were as previously reported. 1, 2 In brief, conventional criteria were used for definition of engraftment, GVHD, rejection and relapses. Chimerism was evaluated in BM and/or peripheral blood cells (granulocytes and mononuclear cells) using HLA allele analysis using the RSCA method and/or by quantitative molecular genotype analysis using 15 markers. 1 This method was also used to analyze DNA from biopsy material taken from GVHD skin lesions to evaluate the presence of donor cells. Time to CB engraftment was defined as the time to sustained ANC of CB origin (CB-ANC)40.5 Â 10 9 /l. This was determined as a function of the total ANC and the percentage of CB DNA determined by the above methods in the DNA obtained from granulocytes after the transplant.
Evaluation of lymphocyte populations
Lymphocyte populations were evaluated according to the consensus protocol of the AlloStem IP WP-III cooperative group. Peripheral blood samples were collected before the CBT and at 3-month intervals thereafter. Lymphocyte subpopulations were analyzed in whole blood with fivecolor flow cytometer (FC 500; Beckman Coulter Inc., Fullerton, CA, USA) using MoAb: anti-CD19, anti-CD56, anti-CD3, anti-CD4 and anti-CD8 (all from Beckman Coulter), and anti-CD4 and anti-CD25 (from BD Biosciences, San Jose, CA, USA). Anti-CD27 (BD Biosciences) and CD45RO (SEROTEC, Oxford, UK) MoAb were used for assessment of cells of naive, effector and memory phenotypes. 4 These subpopulations were respectively identified by the CD45RO
þ phenotypes. Cells of both the effector and memory phenotypes were regarded as committed (nonnaive) cells. The samples were treated with lysis solution VersaLyse (Beckman Coulter) and the absolute count determination was performed using Flow-Count Fluorospheres (Beckman Coulter).
Evaluation of CMV-specific T cells
Frequency of CMV-specific CD3 þ CD8 þ T cells was assessed by staining with phycoerythrin (PE)-labeled pentamers and tetramers restricted by HLA-A*0101, HLA-A*0201, HLA-A*2402 and HLA-B*3502. P-VYA, P-NVL and P-IPS pentamers were purchased from Proimmune (Oxford, UK). T-QYD and T-YSE tetramers, tetramerized from biotinylated monomers by adding 10% of the calculated amount of streptavidin conjugated with PE (Molecular Probes, Eugene, OR, USA) every 30 min at 4 1C in the dark, with continuous rotation; when 100% of streptavidin was added, tetramers were stored in the dark at 4 1C until used. Only those patients who expressed these HLA class I alleles were eligible for the study. Cryopreserved mononuclear cells were incubated with suitable pentamers and tetramers for 20 min at room temperature. Cells were then stained with anti-CD8-FITC (Proimmune) and anti-CD3-PC5 (Beckman Coulter) for 15 min at 4 1C. Samples were analyzed by flow cytometry in the presence of propidium iodide (BD Biosciences) to discard dead cells.
Evaluation of signal joint TCR excision circles
Isolation of CD3
þ CD4 þ and CD3 þ CD8 þ cells from PBMC was performed with magnetic microbeads (MACS; Miltenyi, Gladbach, Germany) according to the manufacturer's protocol. Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacturer's specifications. DNA concentration was determined by spectrophotometry. The Light Cycler PCR and detection system (Roche Diagnostic, Mannheim, Germany) was used for the amplification and quantification of signal joint TCR Immune reconstitution after CB/TPD transplants T Martín-Donaire et al excision circles (sjTRECs) as previously described. 5 Primers for the amplification of the sjTRECs sequence were 5 0 -CAC-ATC-CCT-TTC-AAC-CAT-gCT-3 0 (forward) and 5 0 -CCC-Agg-ATg-gAA-AAC-ACA-gTg-3 0 (reverse). For the amplicon detection two different probes were used. One probe was labeled at the 5 0 -end with the Light CyclerRed 640 fluorophore (5 0 -LC640-TCA-CgA-gTT-gCA-ATg-ACA-AgT-TCA-gCC-PH-3 0 ) and the other at the 3 0 -end with fluorescein (5 0 -gCC-CTg-TCT-gCT-CTT-CAT-TCACCg-T-FL-3 0 ; Tibmolbiol, Berlin, Germany). A standard curve was prepared using a plasmid that includes a fragment of 375 bp of the sjTREC sequence. PCR assays were carried out using 5 ml samples of known DNA concentration in a final volume of 30 ml. The number of cells used in each PCR amplification was calculated by dividing the total picograms of DNA in the 5 ml sample by 6 (the approximate weight in picograms of the total amount of DNA in a diploid somatic human cell, as described in the Roche Diagnostic LightCycler FastStart protocol). Results were referred to 300 000 cells or reported as absolute numbers of sjTRECs per liter, calculated on the basis of the absolute counts of CD3 þ CD4 þ and CD3 þ CD8 þ subpopulations determined by flow cytometry. The sensitivity of our assay was of 20 copies.
Statistical methods
Overall survival was estimated by Kaplan-Meier method. Cumulative incidences of recovery of the different lymphocyte populations were determined by competing risk analysis using NCSS 2004 statistical package (Kaysville, UT, USA). Death without recovery was regarded as a competing event and no recovery as censored observations. As data of lymphocyte populations were not normally distributed their logarithms were used for the analysis of the influence of different factors (age, TBI in the conditioning regimen, CD34 þ cell dose in the transplanted CB unit, GVHD and development of CMV reactivations) on immune reconstitution (Lilliefors correction of the Kolmogorov-Smirnov test). A general linear model (analysis of variance-ANOVA) was used to compute the time effect (within-subjects), the group effect (between-subjects) and the interaction effect. All P values were two sided and values p0.05 were regarded as indicative of statistical significance. These methods were also used to evaluate the time effect (within-subjects) on the values of sjTRECs in CD4 þ and CD8 þ T cells. The SPSS 14.0 statistical package (Chicago, IL, USA) was used for the statistical analysis of the study.
Results
Patient characteristics
Characteristics of the patients, including demographics, diagnosis and pretransplant serologies are shown in Table 1 .
Transplanted cord blood units Cellularity and compatibility data of the transplanted units are shown in Table 2 .
HLA mismatches were 0-3 (median, 1) for class IA and B loci (serologic) and class II DRB1 (allelic), both GVHD and rejection wise. Infused total nucleated cells (TNC; 
Third party donor cells
The TPD were haploidentical in 18 instances and 12 (from related or unrelated donors) did not share a haplotype (Table 3 Table 4 ). Overall survival was 68% after 3 years ( Figure 1 ). Primary causes of deaths were toxicity in two (VOD and MOF), a-GVHD, relapse, secondary EBV-related lymphoproliferative disease (one each) and opportunistic infections (four). Sequential evaluation of chimerism showed initial predominance of TPD DNA, both in granulocytes and mononuclear circulating and marrow cells, followed by progressive replacement by cells from the CB transplant. One patient, showed, after achieving full CB chimerism, appearance of recipient DNA in increasing proportions from 2.5 months after the transplant, a relapse being Immune reconstitution after CB/TPD transplants T Martín-Donaire et al documented on month 17. Relapses also occurred in three other patients at months 7, 9 and 12 after the transplant without previous detection of loss of the full CB chimerism.
Post-transplant events related to immune recovery Post-engraftment opportunistic infections were a major cause of morbidity and mortality. Polyoma virus-related hemorrhagic cystitis and CMV reactivations were the most frequent. Altogether, there were 31 episodes of CMV reactivations (two resulting in death) observed in 28 of the 30 patients included in this study who were seropositive before the transplant, the incidence of reactivations decreasing after the fourth month ( Figure 2 ).
Manifestations of a-GVHD of any grade developed in 19 patients, initiated after 11-105 (median, 33) days from the transplant. These reached grade II in seven patients and grades III-IV in two, being the cause of death in one. Two were refractory to corticosteroid therapy and responded to infusions of mesenchymal stem cells (MSC). Manifestations of chronic GVHD developed in 9 of 26 patients at risk (34.6%), limited in all but 3 (Table 5 ). DNA analysis of skin biopsy material from four of these patients showed CB DNA in two and TPD-DNA in none. As previously stated, relapses occurred in four.
Post-transplant recovery of lymphocyte populations
The very low total absolute counts of circulating lymphocytes precluded separate chimerism analysis of the different subpopulations before the patients achieved full CB chimerism. Figure 3 
inclusive of regulatory and activated T cells remained below normal levels up to 36 months for more than 75% of the patients (data not shown). Cells of this phenotype were not further evaluated. 
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The only factors that appeared to significantly influence immune recovery were: TBI and development of GVHD as factors for slower B-cell recovery (P values 0.024 and 0.014); TBI as a factor for slower recovery of committed CD8 þ cells (P ¼ 0.046); and CMV reactivations as a factor for earlier higher levels of CD3 þ CD8 þ cells (Po001; Figure 6 ). ). Patient data showed wide variation at the different evaluation times, although a general pattern was observed: relatively high pretransplant values; undetectable or very low values by the third month post transplant; and thereafter values persistently similar or higher than those observed before the transplants and in postnatal normal controls (both individuals of similar age and 6-to 24-month-old children), up to the longest follow-up of 2 years (Table 6 ; Figure 7 ). This general pattern was observed in individuals of all ages (26-58), with remarkable parallelism in the results of CD3 þ CD4 þ and CD3 þ CD8 þ populations (Figure 8 ). Statistical analyses of these data showed the following significant differences: (1) month 3 results lower than those of later determinations (Po0.001); (2) month 6 results lower than results in CB (P ¼ 0.008 for CD4 þ and P ¼ 0.006 for CD8 þ ) and children (P ¼ 0.004 for CD4 þ and P ¼ 0.001 for CD8 þ ), but not lower than in Immune reconstitution after CB/TPD transplants T Martín-Donaire et al normal adults; (3) month 6 results lower than those of month 18 (P ¼ 0.019) and (4) month 18 results no different from those in CB and children but higher than those of normal adults in the CD8 þ cells (P ¼ 0.001).
CMV specific CD8 þ T cells CMV specific CD8 þ T cells were sequentially evaluated in nine patients who were CMV seropositive before the transplant and were detected in six of the seven with posttransplant CMV reactivations, levels progressively decreasing after the last episodes (Table 7, Figure 9 ). It can be assumed that these specific cells derived from the CB transplant in the five patients (no. 3 to 6 and 8) who were in full CB chimerism. Patient no. 7 was in mixed chimerism of CB and patient cells, the derivation of the CMV cells from either of these not being discernible. No circulating CD8 þ CMV-specific T cells were detected in one patient (no. 9) who had a single episode or CMV reactivations and in the two (no. 1 and 2) who had none, up to 12-24 months after transplantation. Results are expressed in copies per 300 000 cells (median and ranges).
Immune reconstitution after CB/TPD transplants T Martín-Donaire et al
Discussion
The strategy of dual CB/TPD-MHSC results in high rates of CB engraftment and full CB chimerism, even when using units of cell content lower than the thresholds of 2.5 Â 10 7 / kg TNC and 0.17 Â 10 6 /kg CD34 þ cells. 1, 2, 6, 7 This possibility is especially convenient for adult patients, who represent the greatest demand for HSC transplants. With this strategy, we have observed low incidence of severe GVHD (with no detection of DNA from the TPD in the biopsies of the skin lesions) and relapses (suggesting a valuable GVT effect) and a high incidence of post-engraftment opportunistic infections, as is the case for CBT using other strategies.
1,2 The most frequent infections were hemorrhagic cystitis caused by polyoma virus and CMV reactivations, whose incidence decreased after the fourth month, indicating the development of some degree of protective immunity.
Compared to peripheral blood of healthy adults, CB has higher absolute counts of total lymphocytes, B cells, NK cells and T cells (CD3
, the majority of them showing naive phenotype (CD45RA). 8 Nevertheless, due to the reduced volume of CB collected, recipients of CB transplants receive lower numbers of these cells than recipients of T-cell undepleted HSC transplants from other sources. In addition, the transplanted CB T cells may experience in vivo purging as a consequence of the use of ATG as part of the conditioning, aside from possible rejection by the post-conditioning residual reactive capacity of the recipient immune system. This may be favored by the low grade of HLA compatibility of most allogeneic CBT. All these may contribute to the profound lymphopenia and the low number of sjTRECs bearing T cells observed in our patients in the initial weeks after the transplant, and may explain a low contribution of the CB-transplanted postthymic lymphocytes to post-transplant immune reconstitution.
Our data on recovery of the lymphocyte populations show a relatively early reconstitution of both the NK and B cells, whose cradles are peripheral lymphoid organs and BM, and slower development of the T cells, especially of the CD3 þ CD4 þ subsets. These data agree with those previously reported for CBT without the support of TPD-MHSC 9, 10 and are consistent with the observed favorable GVT effect and low incidence of GVHD, together with a high incidence of opportunistic infections.
For the neogenesis of T cells from HSC, no cradles other than the thymus are known. [11] [12] [13] Recent thymic emigrates (RTE) are T cells of naive phenotype, bearers of sjTRECs. A high correlation between the number of naive cells characterized by a CD45 þ RA þ CD31 þ phenotype and the number of CD4 þ cells bearing sjTRECs has been well documented, although numbers of sjTREC bearing cells in peripheral blood reflect a balance between thymic activity and the dilution effect of later divisions of the RTE. [14] [15] [16] Reports on sjTRECs after CBT in adults are few and somewhat discrepant. 16, 20 Our data on serial sjTREC assays in patients and normal controls suggest that adults receiving dual CB/TPD-MHSC transplants according to our protocol maintain, compared to the normal controls (adults, children and CB samples), a substantial degree of Figure 8 Signal joint TCR excision circle (sjTREC) levels in CD4
þ cells and CD8 þ cells. Individual data. Graphs are ordered by patient's age (26-58, median 34): similar pattern observed both in younger and older patients. thymic function, that may be an important factor for the recovery of the T-cell populations. In addition, our data on the course of recovery of cells of naive, effector and memory phenotypes within the CD3 þ CD4 þ and CD3 þ CD8 þ subpopulations are consistent with expansion of naive RTE generated in the recipient's thymus from the CB-HSC, that could result from the combined effects of the post-transplant lymphopenic environment (homeostatic expansion) and exposure to antigenic stimuli. [11] [12] [13] This could be an explanation for the observed lagging recovery of the absolute numbers of circulating cells of naive phenotype relative to the faster recovery of the committed (effector and memory) subsets, despite a maintained thymic cell output that, estimated on the basis of levels of sjTRECs, is not poorer than in normal infantile and adult controls. The observed late initiation of the T-cell recovery in our patients does not support an initial predominant contribution of the expansion of the naive T cells infused Figure 9 CMV-specific cells. CMV-specific CD8 þ T cells were sequentially evaluated in nine CMV pretransplant seropositive patients using specific CMV pentamers and tetramers. Patients no. 1 and 2 had no CMV reactivations after the transplant. Patients no. 3 to 9 had CMV reactivations after different intervals following the transplant (represented by inverted arrows in each patient). P ¼ pentamer for HLA matched patient; C ¼ pentamer for HLA matched cord blood.
with the CBT. This may be, at least to a certain extent, a consequence of the purging effect of the ATG given as part of the conditioning.
The only significant associations shown by our data were TBI and development of GVHD with slower B-cell recovery (P values 0.24 and 0.14), development of CMV reactivations with earlier higher levels of CD3 þ CD8 þ cells (Po0.001) and TBI with slower recovery of committed CD8 þ cells (P ¼ 0.046). Also observed were other differences that could be of biological relevance, whose lack of statistical significance could be related to the low number of patients in the study.
Despite the slow emergence of the T-cell populations, the development of protective antiviral cellular immunity is denoted by the declining incidence of CMV reactivations after the initial 4 months observed in our patients. Clearly relevant in this regard is the observed development of CD8 þ CMV-specific T cells derived from the CB graft related to CMV reactivations. Early appearance of T cells specific for different herpes viruses detected by a different methodology has been described in recipients of CBTs, even in the absence of clinical evidence of infection, and has been correlated with higher GVT effect.
18-20
Although we do not have data on chimerism specific for circulating NK cells within the initial 3 months, as patients initially develop double TPD/CB chimerism, both in circulating granulocytes and mononuclear cells that evolves to full CB chimerism within 3 months, they could initially have NK cells derived from the TPD. In case of killer cell Ig-like receptor incompatibility with the recipient such cells could provide some degree of NK cell-dependent innate immune protection that might contribute to the GVT effect. 21 To evaluate possible effects of the TPD cells on the immune reconstitution of the recipient, as both induction of sensitation and tolerance are conceivable possibilities, we have done MLC of post-transplant lymphocytes from the recipient against the TPD lymphocytes, but no conclusive results have been obtained (data not shown). On the other hand, the early recovery of the ANC that results from the 'bridge' engraftment of the TPD MHSC provides not only protection against bacterial and fungal infections, but also capacity to withstand treatments with gancyclovir and other antimicrobials with myelosuppressive side effects. However, the most effective therapeutic actions for these infectious complications would be those that could enhance development of effective immune reactivity, which basically requires T cells reactive against the causing pathogens. Actions that could optimize immune recovery of recipients of CBT, and thus final outcomes, include those that are able to enhance thymic T-cell output and endogenous development of effector cells (vaccinations). Nevertheless, it is also conceivable that beneficial effects could result from the infusion of TPD selected/expanded populations of cells, other than MHSC, that could improve the supportive capacity of the hematopoietic microenvironment, to act as immunomodulators or to provide adoptive immunotherapy. 20, [22] [23] [24] Cells that could provide benefit through these mechanisms in terms of GVHD, GVT and antimicrobial immunity and that deserve evaluation include MSC, T-reg, NK cells and pathogen-specific effector lymphocytes. 20 The possible benefits of cells that may produce immunomodulation include less need for immunosupression, that could lead to avoiding ATG as part of the conditioning regimen.
In conclusion, by reducing the nonhematologic toxic effects of the conditioning regimen as well as the incidence of neutropenia-related infections, the strategy of dual CB/ TPD-MHSC makes CBT feasible as a first choice option for a large number of patients of wide age range who lack a related HLA-compatible enough donor. Patients transplanted with this procedure have early post-transplant deep lymphopenia, followed by relatively early recovery of NK and B cells and much later recovery of T-cell subpopulations, to which both thymic neogenesis and postthymic expansion of naive RTE contribute. Additional research is needed to further evaluate the possibilities of optimizing post-transplant innate and adaptive immune recovery for a better balance between GVT and protection against pathogens vs risk of GVHD. Cell therapy procedures appear to be promising.
